In a ground breaking development, material engineers at Stanford University has discovered a novel hydrogel based drug delivery system that will lead to revolutionize the diabetes treatment. A report published in November 2023, the report reveals that this new system is able to transform the daily or weekly injection of diabetes medication. This include Trulicity, Ozempic, Victoza, and Mounjaro into a single injection just once in every four months.
This new technology has the ability to significantly improve the lives of millions of people globally having diabetic problem. This new drug delivery system uses an innovative polymer that will release the medication over a certain period of time. This makes the patient able to receive a consistent and controlled dose of diabetes and weight control medicine.
The system is fully tested by the material engineers, they are optimistic about the potential for human use. With this new development diabetic people are able to enjoy a more efficient, convenient, and effective hydrogel based drug delivery treatment regimen. It will help in freeing them from the daily burden of time. This innovation technology will enhance the quality of life for those living with diabetic issues. This drug will aid in mimicking the hormone glucagon such as peptide 1. It will also help those people who are looking for losing their weight.
As per the research conducted by Coherent Market Insights, the global hydrogel-based drug delivery system market is poised to jump from US$ 7.95 billion in 2024 to US$ 12.40 billion by 2031. Sales are expected to soar at a CAGR of 6.6% CAGR between 2024 and 2031. Growth is being driven by rising incidences of chronic diseases and growing demand for more advanced treatment. Chronic disease such as diabetes, cancer needs long term treatment.
North America is set to hold lion’s share in the global hydrogel based drug delivery system market followed by Asia Pacific. Large number of pharmaceutical companies and government regulatory policies will help North America to grow. On the other hand, growth in Asia Pacific region is driven by increasing healthcare spending.
Key players in the market are focusing on research and development to provide more affordable solutions. By developing cost-effective alternatives these players are able to cater to a large number of healthcare providers. “Growing demand for cost effective solutions and rising prevalence of chronic disease will provide an opportunity for growth,” says lead pharmaceutical analyst Ghanshyam Shrivastava.
